JP2003012668A5 - - Google Patents

Download PDF

Info

Publication number
JP2003012668A5
JP2003012668A5 JP2002126869A JP2002126869A JP2003012668A5 JP 2003012668 A5 JP2003012668 A5 JP 2003012668A5 JP 2002126869 A JP2002126869 A JP 2002126869A JP 2002126869 A JP2002126869 A JP 2002126869A JP 2003012668 A5 JP2003012668 A5 JP 2003012668A5
Authority
JP
Japan
Prior art keywords
group
compound according
alkyl
hydrogen atom
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002126869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003012668A (ja
JP3602513B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2002126869A priority Critical patent/JP3602513B2/ja
Priority claimed from JP2002126869A external-priority patent/JP3602513B2/ja
Publication of JP2003012668A publication Critical patent/JP2003012668A/ja
Application granted granted Critical
Publication of JP3602513B2 publication Critical patent/JP3602513B2/ja
Publication of JP2003012668A5 publication Critical patent/JP2003012668A5/ja
Priority to NL300927C priority patent/NL300927I9/nl
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002126869A 2001-04-27 2002-04-26 アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 Expired - Lifetime JP3602513B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2002126869A JP3602513B2 (ja) 2001-04-27 2002-04-26 アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
NL300927C NL300927I9 (nl) 2001-04-27 2018-01-31 Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001132775 2001-04-27
JP2001-132775 2001-04-27
JP2002126869A JP3602513B2 (ja) 2001-04-27 2002-04-26 アゾリル基を有するキノリン誘導体およびキナゾリン誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004101164A Division JP2004224800A (ja) 2001-04-27 2004-03-30 アゾリル基を有するキノリン誘導体およびキナゾリン誘導体

Publications (3)

Publication Number Publication Date
JP2003012668A JP2003012668A (ja) 2003-01-15
JP3602513B2 JP3602513B2 (ja) 2004-12-15
JP2003012668A5 true JP2003012668A5 (enExample) 2004-12-16

Family

ID=26614489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002126869A Expired - Lifetime JP3602513B2 (ja) 2001-04-27 2002-04-26 アゾリル基を有するキノリン誘導体およびキナゾリン誘導体

Country Status (1)

Country Link
JP (1) JP3602513B2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815241B2 (en) 2005-11-07 2014-08-26 Eisai R&D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4383870B2 (ja) * 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
JP5368096B2 (ja) * 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008093855A1 (ja) * 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
HUE058271T2 (hu) 2016-09-13 2022-07-28 Kyowa Kirin Co Ltd Tivozanibot tartalmazó gyógyászati készítmény
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US8815241B2 (en) 2005-11-07 2014-08-26 Eisai R&D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor

Similar Documents

Publication Publication Date Title
JP2005500311A5 (enExample)
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
JP2006508065A5 (enExample)
JP2004501930A5 (enExample)
CA2445333A1 (en) Quinoline derivatives and quinazoline derivatives having azolyl group
JP2006517572A5 (enExample)
JP2010524932A5 (enExample)
JP2004532209A5 (enExample)
JP2011500658A5 (enExample)
WO2005037781A3 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JP2006509749A5 (enExample)
RU2001132139A (ru) Имидазохинолины с сульфонамидными или сульфамидным замещением
JP2007508359A5 (enExample)
RU2001112421A (ru) Бензоилциклогександионы, способ их получения и их применение в качестве гербицидов и регуляторов роста растений
RU2002115263A (ru) 5-членные N-гетероциклические соединения, обладающие гипогликемической и гиполипидемической активностью
JP2009507896A5 (enExample)
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
JP2005511547A5 (enExample)
YU24503A (sh) Novi tiadiazoli i oksadiazoli i njihova upotreba kao inhibitora fosfodiesteraze-7
JP2005530811A5 (enExample)
JP2005518357A5 (enExample)
JP2002520316A5 (enExample)
JP2006503845A5 (enExample)
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
JP2007507494A5 (enExample)